Renal Cell Carcinoma News and Research

Latest Renal Cell Carcinoma News and Research

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

IDMC recommends continuation of Argos’ ADAPT phase 3 trial of AGS-003 in mRCC patients

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

Nivolumab and pembrolizumab therapies continue to show promise against advanced melanomas

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

Lenvatinib-everolimus combination extends PFS in patients with mRCC versus everolimus alone

AstraZeneca presents preliminary data from AZD6094-AZD9291 combination trial for treatment of NSCLC

AstraZeneca presents preliminary data from AZD6094-AZD9291 combination trial for treatment of NSCLC

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Clinical utility of Caris Molecular Intelligence in five studies to be presented at ASCO 2015

Research shows HEOR data can be used to better determine value-based reimbursement strategies

Research shows HEOR data can be used to better determine value-based reimbursement strategies

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Novartis to highlight strength of its expanded oncology portfolio at ASCO 2015

Updated data from PROCLAIM national patient registry presented at 51st ASCO

Updated data from PROCLAIM national patient registry presented at 51st ASCO

SNPs predict sunitinib outcome in mRCC

SNPs predict sunitinib outcome in mRCC

‘Real-world’ sunitinib findings support trial results

‘Real-world’ sunitinib findings support trial results

RCC benefit independent of sorafenib, sunitinib sequence order

RCC benefit independent of sorafenib, sunitinib sequence order

First-line axitinib ‘feasible’ in advanced, metastatic RCC

First-line axitinib ‘feasible’ in advanced, metastatic RCC

Immunotherapy for kidney cancer - Phase 3 update from Argos Therapeutics at ASCO

Immunotherapy for kidney cancer - Phase 3 update from Argos Therapeutics at ASCO

Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

Honokiol extract holds promise as adjunct treatment for bladder and kidney cancers

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

UNM Cancer Center enrolls first patient in phase 3 international clinical trial for kidney cancer vaccine

Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Bionomics to present BNC105 trial results of metastatic renal cancer at Asian Oncology Summit

Limited anticancer role for preoperative statins in localised RCC setting

Limited anticancer role for preoperative statins in localised RCC setting

IMDC prognostic model valid in second-line RCC therapy

IMDC prognostic model valid in second-line RCC therapy

Alternating sunitinib, everolimus not supported in advanced RCC

Alternating sunitinib, everolimus not supported in advanced RCC

HRQoL benefit of alternative sunitinib dosing schedule in RCC patients

HRQoL benefit of alternative sunitinib dosing schedule in RCC patients

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.